Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||The disclosure covers the preparation of the compound, 6.alpha.,9.alpha.-difluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna -1,4-diene-3,20-dione 17.alpha.,21-diacetate, (1) and methods and formulations for its anti-inflammatory use topically, orally and parenterally.|
|Inventor(s):||Ayer; Donald E. (Kalamazoo, MI), Schlagel; Carl A. (Kalamazoo, MI), Flynn; Gordon L. (Ann Arbor, MI)|
|Assignee:||The Upjohn Company (Kalamazoo, MI)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.